CKD-388 Tab.

DRUG2 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Chronic Hepatitis b

Phase 1

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects

Chong Kun Dang PharmaceuticalChronic Hepatitis b

Start: 2021-02-26End: 2021-05-18Target: 56Updated: 2020-12-21

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

CompletedNCT05189288

Chong Kun Dang PharmaceuticalChronic Hepatitis b

Start: 2022-01-14End: 2022-04-15Updated: 2022-09-28